217 related articles for article (PubMed ID: 29864484)
1. Toxicological study of a new doxorubicin-loaded pH-sensitive liposome: A preclinical approach.
de Oliveira Silva J; Miranda SEM; Leite EA; de Paula Sabino A; Borges KBG; Cardoso VN; Cassali GD; Guimarães AG; Oliveira MC; de Barros ALB
Toxicol Appl Pharmacol; 2018 Aug; 352():162-169. PubMed ID: 29864484
[TBL] [Abstract][Full Text] [Related]
2. Slow infusion rate of doxorubicin induces higher pro-inflammatory cytokine production.
Tien CC; Peng YC; Yang FL; Subeq YM; Lee RP
Regul Toxicol Pharmacol; 2016 Nov; 81():69-76. PubMed ID: 27494949
[TBL] [Abstract][Full Text] [Related]
3. Reduction of the cardiotoxicity of doxorubicin in rabbits and dogs by encapsulation in long-circulating, pegylated liposomes.
Working PK; Newman MS; Sullivan T; Yarrington J
J Pharmacol Exp Ther; 1999 May; 289(2):1128-33. PubMed ID: 10215696
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of acute toxicity and in vitro antitumor activity of a novel doxorubicin-loaded folate-coated pH-sensitive liposome.
de Oliveira Silva J; Fernandes RS; de Alcântara Lemos J; Cassali GD; de Paula Sabino A; Townsend DM; Oliveira MC; de Barros ALB
Biomed Pharmacother; 2023 Sep; 165():115280. PubMed ID: 37541172
[TBL] [Abstract][Full Text] [Related]
5. Folate-coated, long-circulating and pH-sensitive liposomes enhance doxorubicin antitumor effect in a breast cancer animal model.
de Oliveira Silva J; Fernandes RS; Ramos Oda CM; Ferreira TH; Machado Botelho AF; Martins Melo M; de Miranda MC; Assis Gomes D; Dantas Cassali G; Townsend DM; Rubello D; Oliveira MC; de Barros ALB
Biomed Pharmacother; 2019 Oct; 118():109323. PubMed ID: 31400669
[TBL] [Abstract][Full Text] [Related]
6. Liposomes co-encapsulating doxorubicin and glucoevatromonoside derivative induce synergic cytotoxic response against breast cancer cell lines.
Novais MVM; Gomes ER; Miranda MC; Silva JO; Gomes DA; Braga FC; Pádua RM; Oliveira MC
Biomed Pharmacother; 2021 Apr; 136():111123. PubMed ID: 33486211
[TBL] [Abstract][Full Text] [Related]
7. Comparative long-term study of the toxicities of free and liposome-associated doxorubicin in mice after intravenous administration.
Gabizon A; Meshorer A; Barenholz Y
J Natl Cancer Inst; 1986 Aug; 77(2):459-69. PubMed ID: 3461207
[TBL] [Abstract][Full Text] [Related]
8. A folate modified pH sensitive targeted polymeric micelle alleviated systemic toxicity of doxorubicin (DOX) in multi-drug resistant tumor bearing mice.
Li X; Yang X; Lin Z; Wang D; Mei D; He B; Wang X; Wang X; Zhang Q; Gao W
Eur J Pharm Sci; 2015 Aug; 76():95-101. PubMed ID: 25917524
[TBL] [Abstract][Full Text] [Related]
9. Doxorubicin-loaded nanocarriers: A comparative study of liposome and nanostructured lipid carrier as alternatives for cancer therapy.
Fernandes RS; Silva JO; Monteiro LOF; Leite EA; Cassali GD; Rubello D; Cardoso VN; Ferreira LAM; Oliveira MC; de Barros ALB
Biomed Pharmacother; 2016 Dec; 84():252-257. PubMed ID: 27664949
[TBL] [Abstract][Full Text] [Related]
10. Estrogen-anchored pH-sensitive liposomes as nanomodule designed for site-specific delivery of doxorubicin in breast cancer therapy.
Paliwal SR; Paliwal R; Pal HC; Saxena AK; Sharma PR; Gupta PN; Agrawal GP; Vyas SP
Mol Pharm; 2012 Jan; 9(1):176-86. PubMed ID: 22091702
[TBL] [Abstract][Full Text] [Related]
11. pH-sensitive doxorubicin-tocopherol succinate prodrug encapsulated in docosahexaenoic acid-based nanostructured lipid carriers: An effective strategy to improve pharmacokinetics and reduce toxic effects.
Lages EB; Fernandes RS; Andrade MMS; Paiyabhroma N; de Oliveira RB; Fernandes C; Cassali GD; Sicard P; Richard S; Branco de Barros AL; Ferreira LAM
Biomed Pharmacother; 2021 Dec; 144():112373. PubMed ID: 34794238
[TBL] [Abstract][Full Text] [Related]
12. Mechanistic insights into the intracellular release of doxorubicin from pH-sensitive liposomes.
Dos Reis SB; de Oliveira Silva J; Garcia-Fossa F; Leite EA; Malachias A; Pound-Lana G; Mosqueira VCF; Oliveira MC; de Barros ALB; de Jesus MB
Biomed Pharmacother; 2021 Feb; 134():110952. PubMed ID: 33348307
[TBL] [Abstract][Full Text] [Related]
13. Dual-pH Sensitive Charge-Reversal Drug Delivery System for Highly Precise and Penetrative Chemotherapy.
Chen W; Li J; Xing Y; Wang X; Zhang H; Xia M; Wang D
Pharm Res; 2020 Jul; 37(7):134. PubMed ID: 32642819
[TBL] [Abstract][Full Text] [Related]
14. pH-Sensitive, Long-Circulating Liposomes as an Alternative Tool to Deliver Doxorubicin into Tumors: a Feasibility Animal Study.
Silva JO; Fernandes RS; Lopes SC; Cardoso VN; Leite EA; Cassali GD; Marzola MC; Rubello D; Oliveira MC; de Barros AL
Mol Imaging Biol; 2016 Dec; 18(6):898-904. PubMed ID: 27172938
[TBL] [Abstract][Full Text] [Related]
15. In vivo evaluation of a new polymer-lipid hybrid nanoparticle (PLN) formulation of doxorubicin in a murine solid tumor model.
Wong HL; Rauth AM; Bendayan R; Wu XY
Eur J Pharm Biopharm; 2007 Mar; 65(3):300-8. PubMed ID: 17156986
[TBL] [Abstract][Full Text] [Related]
16. A Novel Long-circulating DOX Liposome: Formulation and Pharmacokinetics Studies.
Xiao P; Zhao J; Huang Y; Jin R; Tang Z; Wang P; Song X; Zhu H; Yang Z; Yu N
Pharm Nanotechnol; 2020; 8(5):391-398. PubMed ID: 32787769
[TBL] [Abstract][Full Text] [Related]
17. Tumor-specific pH-responsive peptide-modified pH-sensitive liposomes containing doxorubicin for enhancing glioma targeting and anti-tumor activity.
Zhao Y; Ren W; Zhong T; Zhang S; Huang D; Guo Y; Yao X; Wang C; Zhang WQ; Zhang X; Zhang Q
J Control Release; 2016 Jan; 222():56-66. PubMed ID: 26682502
[TBL] [Abstract][Full Text] [Related]
18. Nanometronomic treatment of 4T1 breast cancer with nanocaged doxorubicin prevents drug resistance and circumvents cardiotoxicity.
Mazzucchelli S; Bellini M; Fiandra L; Truffi M; Rizzuto MA; Sorrentino L; Longhi E; Nebuloni M; Prosperi D; Corsi F
Oncotarget; 2017 Jan; 8(5):8383-8396. PubMed ID: 28039473
[TBL] [Abstract][Full Text] [Related]
19. Hyaluronic acid modified pH-sensitive liposomes for targeted intracellular delivery of doxorubicin.
Paliwal SR; Paliwal R; Agrawal GP; Vyas SP
J Liposome Res; 2016 Dec; 26(4):276-87. PubMed ID: 26784587
[TBL] [Abstract][Full Text] [Related]
20. Continuous electrocardiogram reveals differences in the short-term cardiotoxic response of Wistar-Kyoto and spontaneously hypertensive rats to doxorubicin.
Hazari MS; Haykal-Coates N; Winsett DW; Costa DL; Farraj AK
Toxicol Sci; 2009 Jul; 110(1):224-34. PubMed ID: 19407338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
